Fate Therapeutics, Inc (FATE)

Etorro trading 970x250

About Fate Therapeutics, Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 3535 General Atomics Court, San Diego, CA, United States, 92121

Fate Therapeutics, Inc News and around…

Latest news about Fate Therapeutics, Inc (FATE) common stock and company :

Tentarix Biotherapeutics Emerges with $50 Million Series A
14 Oct, 2021 FinancialContent

Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital.

3 Biotech Stocks to Watch Now
12 Oct, 2021 FinancialContent

Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so. Most ...

Hedge Funds Are Crazy About Fate Therapeutics Inc (FATE)
12 Oct, 2021 Yahoo! Finance

We at Insider Monkey have gone over 873 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th. In this article, we look at what those funds think of Fate Therapeutics Inc (NASDAQ:FATE) based on that […]

Nina Deka: Healthcare Technology Still In Early Stages Of Disruption
07 Oct, 2021 FinancialContent

Nina Deka, Senior Research Analyst at ROBO Global, points out some huge problems in the healthcare industry that are ripe for innovative solutions. After looking at some of five major themes, Nina revisits some stocks from her last appearance like 1Life Healthcare (ONEM) and Teladoc (TDOC) as well as the stories behind Tabula Rasa (TRHC) Akoya BioSciences (AKYA), Catalent (CTLT),...

Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
01 Oct, 2021 Yahoo! Finance

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The o

How The Parts Add Up: FNY Targets $86
28 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Mid Cap Growth AlphaDEX Fund ETF (FNY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $85.63 per unit.

First Week of May 2022 Options Trading For Fate Therapeutics
20 Sep, 2021 FinancialContent

Investors in Fate Therapeutics Inc (FATE) saw new options begin trading this week, for the May 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
15 Sep, 2021 FinancialContent

Peer-Reviewed Cell Stem Cell Publication Highlights Shared Metabolic, Transcriptional, and Functional Features of FT538 and Adaptive NK Cells

Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
15 Sep, 2021 Yahoo! Finance

Peer-Reviewed Cell Stem Cell Publication Highlights Shared Metabolic, Transcriptional, and Functional Features of FT538 and Adaptive NK CellsSAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced today the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell p

Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
14 Sep, 2021 FinancialContent

Positive news versus poor clinical trial results may determine the future of Fate Therapeutics.

Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report?
03 Sep, 2021 Yahoo! Finance

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Fate Therapeutics to Present at Upcoming Investor Conferences
02 Sep, 2021 FinancialContent
Fate Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
02 Sep, 2021 FinancialContent

A Relative Strength Rating upgrade for Fate Therapeutics shows improving technical performance.

Fate Therapeutics Sees Relative Strength Rating Climb To 78
01 Sep, 2021 FinancialContent

Fate Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021
26 Aug, 2021 FinancialContent

Upgrades Scotiabank upgraded the previous rating for Enerplus Corp (NYSE:ERF) from Sector Perform to Sector Outperform. ...

We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
26 Aug, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, Fate Therapeutics...

Peek Under The Hood: FNX Has 12% Upside
25 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Mid Cap Core AlphaDEX Fund ETF (FNX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $112.41 per unit.

Stocks To Watch: Fate Therapeutics Sees Relative Strength Rating Jump To 80
24 Aug, 2021 FinancialContent

A Relative Strength Rating upgrade for Fate Therapeutics shows improving technical performance.

58 Biggest Movers From Friday
23 Aug, 2021 FinancialContent

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell ...

Fate Stock Collapses As Investors Question Durability Of Cancer 'Killers'
20 Aug, 2021 Yahoo! Finance

Fate Therapeutics delivered mixed results for its lymphoma treatments late Thursday, and Fate stock crumbled on Friday.

Benchmarks Pivot Higher Ahead of Volatile Week's End
20 Aug, 2021 FinancialContent

The major indexes rebounded from their pre-market slide soon after the open, with help from big-name tech names, though all three are still on track for weekly losses.

12 Health Care Stocks Moving In Friday's Intraday Session
20 Aug, 2021 FinancialContent

Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 175.07% to $17.33 during Friday's regular session. As of 12:30 ...

38 Stocks Moving In Friday's Mid-Day Session
20 Aug, 2021 FinancialContent

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of ...

Why Fate Therapeutics Stock Is Sliding Today
20 Aug, 2021 FinancialContent

The positive results the company announced after the bell yesterday didn't meet some lofty expectations.

Mid-Morning Market Update: Markets Rise; Deere Beats Q3 Expectations
20 Aug, 2021 FinancialContent

Following the market opening Friday, the Dow traded up 0.42% to 35,041.98 while the NASDAQ rose 0.86% to 14,667.29. The S&P also ...

12 Health Care Stocks Moving In Thursday's After-Market Session
20 Aug, 2021 FinancialContent

Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 30.93% to $5.63 during Thursday's after-market session. Trading volume for ...

11 Health Care Stocks Moving In Friday's Pre-Market Session
20 Aug, 2021 FinancialContent

Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 74.65% to $7.51. The market value of their outstanding shares ...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response
20 Aug, 2021 FinancialContent

Fate Therapeutics Inc(NASDAQ: FATE)revealed an early cutof Phase I data for its FT596 and FT516 programs for ...

Fate Therapeutics Stock Falls on Trial Data for Lymphoma Treatment
20 Aug, 2021 Yahoo! Finance

Fate Therapeutics stock tumbled Friday after the biopharma reported mixed results from a clinical trial of its treatment for B-cell lymphoma. Shares of the San Diego company at last check were off 17% at $71. Another patient who experienced a partial response had to receive an additional anti-cancer treatment about four months later.

Fate Therapeutics, Inc (FATE) is a NASDAQ Common Stock listed in , ,

970x250